Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 26, 2015

View Archived Issues

Ono Pharmaceutical presents novel LPA1 receptor antagonist for BPH

Susceptibility gene for adolescent idiopathic scoliosis identified

CSL Behring enrolls first patient in phase II/III study of rVIIa-FP

Herbal preparation HAT-01 more effective than calcipotriol in psoriasis patients

Merck KGaA and Cancer Research UK report development of Wnt signaling inhibitors

Clementia Pharmaceuticals expands ongoing phase II study of palovarotene

Tapros approved for open-angle glaucoma and ocular hypertension in China

Daiichi Sankyo discloses novel UR-2 receptor antagonists

Amgen submits NDA for etelcalcetide

Lundbeck discloses PDE1 inhibitors

Taiho patents JAK3 inhibitors

Axxam divulges P2X7 antagonists

MedoLution introduces T790M EGFR kinase inhibitors

Oncothyreon patents Chk1 inhibitors

Vitae Pharmaceuticals discloses ROR-gamma inhibitors

FDA grants orphan drug designation to Toca-511/Toca-FC for glioblastoma

PREVENT and Vaxent start phase I trial of multivalent Group A Streptococcus vaccine

MorphoSys and Immatics Biotechnologies establish strategic alliance in cancer

Covance enters into agreement with leading pharmaceutical company for clinical trial monitoring

Hospira and Cerner expand technology agreement

New company Immatics US established to develop adoptive cellular therapies

Asthma exacerbation rates not reduced in tralokinumab trial

Ono Pharmaceutical seeks Japanese approval for carfilzomib

Tracleer approved in Japan for new digital ulcers in patients with systemic scleroderma

European marketing authorization granted for Respreeza

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...